• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Phase 3 Lung Trials Could Be A Big Test For Insmed (INSM)

    Simply Wall St·10/17/2026 01:34:46
    Listen to the news
    • Insmed has highlighted its global PALM Clinical Development Program, which is now running three pivotal Phase 3 trials of once-daily TPIP across serious pulmonary conditions and is planning a fourth in idiopathic pulmonary fibrosis that is expected to start by the first half of 2027.
    • The scale of the PALM program, targeting more than 2,000 patients across four indications, reflects a major resource commitment alongside Insmed's existing BRINSUPRI and ARIKAYCE franchises.
    • Attention now turns to how Insmed's expanding TPIP Phase 3 footprint could influence the broader investment narrative around its future earnings mix.
    Power up your research on Insmed's pulmonary focus by scanning a curated set of late-stage healthcare and biotech names in our 33 healthcare AI stocks that could also be shaping future treatment standards.

    Insmed Investment Narrative Recap

    To own Insmed, you need to buy into a multi-asset respiratory story where ARIKAYCE and BRINSUPRI fund a push into TPIP and other pipeline work. The PALM Phase 3 build out underlines that the business is committing real capital and focus to serious pulmonary disease. That is a long slog. In the near term, the most important swing factor still appears to be clean execution on brensocatib launches and payer access.

    The biggest operational risk remains the timing and quality of commercialization for brensocatib and ARIKAYCE label expansion, along with any regulatory or payer friction that slows uptake. The TPIP news does not materially change that in the near term. It does add future complexity to spending, trial execution, and eventual real-world adherence, which could influence how efficiently Insmed converts its pipeline into revenue.

    Among the recent updates, the reaffirmed 2026 guidance for BRINSUPRI revenue of US$1.25b to US$1.40b and ARIKAYCE revenue of US$450 million to US$470 million is particularly relevant to the TPIP story. Those ranges frame how much internal cash Insmed expects to generate while it runs four large PALM studies and supports upcoming launches.

    If those revenue ranges are met, management may have more room to fund PALM without leaning as heavily on external capital, which matters given the current P/S and past share issuance. If delivery against guidance falls short, the same TPIP program that appears to be a potential growth engine could strain the balance sheet and focus investor attention more sharply on cost discipline and trial risk.

    What The Long Range Insmed Forecast Implies

    Insmed's consensus story ties the PALM program and brensocatib launch plans into a much larger set of numbers. Analysts looking out to 2029 are not just modeling more pulmonary products. They are effectively sketching a different earnings profile for the whole business.

    Insmed's narrative projects US$4.1b revenue and US$1.0b earnings by 2029, built on assumed 70.4% yearly revenue growth and an earnings move from a loss of US$1.2b today to that US$1.0b level in 2029.

    Those projections sit alongside an expected profit margin swing from a loss of 144.4% today to a positive margin of 24.8% in three years. That is a sharp shift in how every incremental dollar of sales would be converted into profit. To get there, Insmed would also need to support rising R&D and commercial spending for TPIP and brensocatib while analysts still assume the business can lift earnings into positive territory.

    Valuation work around these figures leans on that US$4.1b revenue and US$1.0b earnings profile in 2029, paired with a modeled P/E of 56.3x. That multiple is higher than the 16.4x P/E cited for the broader US biotech sector and leaves less room for disappointment if launches slip or the TPIP program does not translate into the profit structure implied in the models.

    Consensus assumptions also bake in share count growth of 2.54% per year over the next three years. That matters because even if Insmed hits the US$1.0b earnings bar, more shares outstanding would spread that profit across a larger base, which affects how much of the future earnings pool each share represents.

    Learn why Insmed's fair value indicates a 105% potential upside to its current price before the market closes that gap.

    NasdaqGS:INSM 1-Year Stock Price Chart
    NasdaqGS:INSM 1-Year Stock Price Chart

    Exploring Other Perspectives

    One alternate take on Insmed focuses heavily on TPIP as the real swing factor. The most optimistic analysts were penciling in US$5.8b of revenue and US$2.4b of earnings by 2029 before this PALM news, far above consensus. That gap shows how sharply opinions can differ, so explore both sets of assumptions for yourself.

    Explore 2 other Insmed fair value estimates, including one that suggests potential upside of up to 287% from the current price.

    The Verdict Is Yours

    Don't just follow the ticker. Dig into the data and build a conviction that's truly your own.

    Looking for more Insmed-like investment ideas?

    If you want to put Insmed in context and build a broader watchlist, use the Simply Wall St Screener to scan for other companies that match the type of risk and reward profile you are comfortable with.

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.